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The Mo1PyF101 enhancer variant of Moloney murine leukemia virus (M-MuLV) has been very useful in investigating
M-MuLV leukemogenesis. When inoculated subcutaneously (sc) into neonatal mice, Mo1PyF101 M-MuLV is attenuated for
development of disease. Previous studies in mice infected with wild-type M-MuLV have revealed several important
preleukemic events, including development of splenic hyperplasia, defects in bone marrow hematopoiesis, and in vivo
generation of MCF viruses that arise by recombination in the uninfected mouse. Mo1PyF101 M-MuLV is defective in inducing
these effects after sc inoculation. In the experiments reported here, a study of Mo1PyF101 M-MuLV infection in rats was
carried out. Wild-type M-MuLV is leukemogenic in rats, but infected rats do not form MCF recombinants since they lack the
necessary endogenous polytropic envelope sequences. Since Mo1PyF101 M-MuLV’s leukemogenic defect is correlated with
a failure to generate MCF recombinants, it seemed possible that wild-type M-MuLV might not have a leukemogenic
advantage over Mo1PyF101 M-MuLV in rats, where MCF recombinants cannot form. Neonatal Fisher F344 rats were
inoculated sc or intraperitoneally by wild-type and Mo1PyF101 M-MuLVs. Surprisingly, Mo1PyF101 M-MuLV was completely
deficient in leukemogenesis in rats when inoculated by either route while wild-type M-MuLV induced lymphoma with the
predicted time course. The leukemogenic defect for Mo1PyF101 M-MuLV resulted from a pronounced defect for establishing
infection in rats. Further studies of wild-type M-MuLV in rats indicated that infection was confined almost exclusively to the
thymus at early times. In mice wild-type M-MuLV establishes substantial infection in other hematopoietic organs such as
spleen and bone marrow as well. Thymic infection was also correlated with a decrease in thymic cellularity at early times.
© 1998 Academic Press
INTRODUCTION
Moloney murine leukemia virus (M-MuLV) is a replica-
tion-competent simple retrovirus. It has been studied
extensively from the point of view of molecular biology
and its ability to induce leukemia in susceptible animals.
When infected into neonatal mice or rats, M-MuLV in-
duces T-lymphoma with mean latencies of 3–4 months in
mice and somewhat longer latencies in rats.
Insertional activation of cellular proto-oncogenes is
the best-understood mechanism in leukemogenesis by
M-MuLV. It involves either readthrough transcription from
the long terminal repeat of an inserted M-MuLV provirus
into an adjacent cellular proto-oncogene or activation of
the proto-oncogene’s own promoter by the enhancer
element in an adjacent LTR (reviewed in (Fan, 1997)).
Studies on M-MuLV-induced tumors have led to the iden-
tification of several novel proto-oncogenes (Cuypers et
al., 1984; Villeneuve et al., 1986; Tsichlis and Lazo, 1991;
Vijaya et al., 1987).
In addition to proto-oncogene activation, it has be-
come clear that in mice other virus-induced events are
important for M-MuLV leukemogenesis (Fan, 1994). In
particular, several early (preleukemic) events have been
identified (Asjo et al., 1985; Davis et al., 1987; Storch et
al., 1985). We have employed an enhancer variant of
M-MuLV, Mo1PyF101 M-MuLV, to study the process of
leukemogenesis (Davis, et al., 1985). Mo1PyF101 M-
MuLV contains enhancer sequences from the F101 strain
of polyoma virus inserted into the M-MuLV LTR between
the M-MuLV enhancers and basal promoter elements (at
position 2150). In vitro, Mo1PyF101 M-MuLV displays
specific infectivity quite comparable to that of wild-type
M-MuLV. However, when inoculated subcutanously into
newborn mice, it shows substantial attentuation for dis-
ease. The reduced pathogenicity is not a result of low-
level infection in vivo (Davis et al., 1985). This has sug-
gested that Mo1PyF101 is unable to infect some cell
type that is required for efficient leukemogenesis.
Comparative studies of wild-type and Mo1PyF101 M-
MuLV in mice have identified a number of preleukemic
events necessary for efficient disease. These include
hematopoietic hyperplasia in the spleen, which appears
to result from a defect in bone marrow hematopoiesis
(Davis et al., 1987; Li and Fan, 1990). The low pathoge-
nicity of Mo1PyF101 M-MuLV is correlated with an in-
ability to form MCF recombinant viruses in vivo (Bright-
man et al., 1991). MCF viruses are recombinants be-
tween the infecting MuLV and endogenous polytropic
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env sequences resident as proviruses in uninfected mouse
cells (Hartley et al., 1977). MCF recombinants have been
implicated in leukemogenesis by a numbers of studies, and
they may play both early and late roles in the disease
process (Fan, 1994). The tight relationship between leuke-
mogenesis and MCF formation is further demonstrated by
Mo1PyF101 M-MuLV. While subcutaneous inoculation of
this virus shows a leukemogenic defect, intraperitoneal (ip)
inoculation of Mo1PyF101 M-MuLV results in leukemo-
genicity equivalent to that of wild-type virus (Belli and Fan,
1994). In parallel with the increased leukemogenicity, ip
inoculation with Mo1PyF101 M-MuLV results in formation
of MCF recombinants (Belli et al., 1995).
When M-MuLV is inoculated into rats, the animals
develop leukemia without the formation of MCF recom-
binants, since rats do not harbor polytropic-related en-
dogenous proviruses that can recombine in the env re-
gion with MuLV. It is also noteworthy that M-MuLV leu-
kemogenesis in rats is less efficient than in mice; one
possibility is that the lower leukemogenicity might result
from the lack of MCF recombinant formation. In this light,
it was interesting to test rats for leukemogenesis by
Mo1PyF101 M-MuLV. Since the leukemogenic defect of
Mo1PyF101 M-MuLV in mice was strongly correlated
with a lack of MCF formation, it seemed possible that
wild-type and Mo1PyF101 M-MuLV would show equiva-
lent leukemogenicity in rats where MCF formation does
not occur. In this report, we describe comparisons of
Mo1PyF101 and wild-type M-MuLV infection in rats.
RESULTS
Leukemogenesis by Mo1PyF101 and wild-type
M-MuLV in rats
For comparison of the leukemogenicity of Mo1PyF101
and wild-type M-MuLV in rats, neonatal Fisher F344 rats
were inoculated sc with wild-type or Mo1PyF101 M-MuLV.
The concentrations in of the particular wild-type M-MuLV
stocks were somewhat lower (5- to 10-fold) than the
Mo1PyF101 M-MuLV stocks. The sc route of inoculation
was chosen since our previous studies in mice indicated
that Mo1PyF101 M-MuLV showed the leukemogenic de-
fect after sc inoculation (Brightman et al., 1991; Davis et al.,
1985). The results are shown in Fig. 1A. In contrast to our
original hypothesis, while wild-type M-MuLV induced leu-
kemia in F344 rats at a rate consistent with reports from
other workers, Mo1PyF101 M-MuLV was nonleukemo-
genic. (The two uninoculated rats and the one Mo1PyF101
M-MuLV-infected animal that died during the time course of
the experiment succumbed to causes unrelated to leuke-
mia). All animals injected with wild-type M-MuLV that died
had large thymic tumors, consistent with the development
of T-lymphoma. Thus, the lack of MCF formation in rats did
not equalize leukemogenicity of Mo1PyF101 and wild-type
M-MuLV in these animals. The different leukemogenicities
for the two viruses was not related to the slightly different
concentrations of the input inocula since Mo1PyF101 M-
MuLV induced no disease, even though it was inoculated at
higher concentration.
In light of the results of Fig. 1A, we next compared
leukemogenesis by Mo1PyF101 and wild-type M-MuLV
after ip inoculation. We previously found that ip inocula-
tion of these two viruses in mice results in comparable
rates of lymphoma development (Belli and Fan, 1994). As
shown in Fig. 1B, Mo1PyF101 was also completely non-
leukemogenic after ip inoculation in newborn rats. Thus,
Mo1PyF101 was completely nonpathogenic in rats, re-
gardless of the route of inoculation. These results indi-
cated that Mo1PyF101 M-MuLV had different behavior in
rats than in mice, where the virus shows attenuated (but
detectable) leukemogenicity after sc inoculation and
wild-type leukemogenicity after ip inoculation.
In vivo and in vitro infection of Mo1PyF101 M-MuLV
in rats
Given the absolute lack of leukemogenicity by
Mo1PyF101 M-MuLV in rats, it was important to investi-
gate the ability of the virus to infect these animals. We
FIG. 1. Leukemogenicity of wild-type and Mo1PyF101 M-MuLV in rats. (A) Neonatal Fisher F334 rats were inoculated subcutaneously with wild-type
or Mo1PyF101 M-MuLV as described under Materials and Methods. Mortality plots are shown. All moribund animals infected with wild-type M-MuLV
showed evidence of lymphoma at necropsy. The behavior of uninfected rats is also shown. (B) Neonatal rats were inoculated intraperitoneally with
the same two viruses and the resulting mortality plots are shown.
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previously showed that in mice, this virus establishes
substantial infection (comparable to wild-type M-MuLV)
in most tissues at preleukemic times (Davis et al., 1986).
The one exception was a defect in early infection in the
bone marrow, which led to the conclusion that early
infection of the bone marrow is important for efficient
leukemogenesis in mice by wild-type M-MuLV (Belli and
Fan, 1994). F344 rats were infected neonatally with
Mo1PyF101 or wild-type M-MuLV by either sc or ip
inoculation, and the extent of infection in different hema-
topoietic organs was determined at various times postin-
fection by infectious center assays. As shown in Table 1,
Mo1PyF101 M-MuLV showed a profound defect in es-
tablishing in vivo infection in rats. This was particularly
evident in sc-infected animals, in which no infection (,1
XC PFU/105 cells) was detected in any of four animals
examined at 2 or 4 weeks of age. The defect for in vivo
infection of Mo1PyF101 M-MuLV was also evident in
ip-infected animals, although at later times (4 and 6
weeks), low-level infection (generally 2 logs less than
that in wild-type M-MuLV-infected rats) was detected in
some thymus or spleen samples. The in vivo defect for
establishing Mo1PyF101 M-MuLV infection in rats was
quite different from infection in mice.
Since Mo1PyF101 M-MuLV did not efficiently estab-
lish infection in rats in vivo, it was important to test if the
virus could efficiently infect rat cells in vitro. We previ-
ously showed that this virus has specific infectivity al-
most equivalent to wild-type M-MuLV during in vitro in-
fection of mouse cells (0.2 vs 1 (Davis et al., 1985)).
However, it was possible that the transcription factors
present in rat cells are unable to support expression
from the Mo1PyF101 M-MuLV LTR. Therefore, the rela-
tive in vitro infectivities of Mo1PyF101 and wild-type
M-MuLV were compared in rat REF52 cells. The standard
XC plaque assay for MuLVs did not work on these cells
(and several other rat lines), due to incompatibility of the
REF52 cells and the XC indicator cells. Therefore, two
other means of assessing viral infectivity were employed.
First, endpoint dilution infections of wild-type and
Mo1PyF101 M-MuLV stocks on both NIH-3T3 and REF52
cells were carried out in triplicate. The cultures were
passaged five times and then assayed for the presence
of infected cells by immunofluorescent staining with an
M-MuLV-specific monoclonal antibody. As shown in Ta-
ble 2, in NIH-3T3 cells, the two virus stocks had similar
infectivities in the range of 106–107 IU/ml. The Mo1PyF101
stock appeared to have a somewhat higher titer than the
wild-type M-MuLV stock. In REF52 cells, the infectivities
for both stocks were substantially lower than that in the
NIH-3T3 cells, consistent with the observations of previ-
ous workers—in the range of 103–104 IU/ml. Indeed, in
NIH-3T3 cells where the virus-positive cultures at the
dilution endpoints were uniformly infected, the higher
dilutions on RE52 cells showed partial infection even
after five transfers. This indicated much less efficient
spread of infection in M-MuLV-infected rat cultures. How-
ever, despite the lower overall infectivity on REF52 cells,
Mo1PyF101 M-MuLV showed approximately the same
infectivity on rat cells as wild-type M-MuLV (within 10-
TABLE 1
Infection of Hematopoietic Tissues in Wild-Type and Mo1PyF101 M-MuLV-Infected Rats
Rat No. Virus Route Age (weeks)
XC PFU/105 cells
Thymus Spleen Bone marrow
10-1 Mo1PyF101 M-MuLV sc 2 0 0 0
10-2 Mo1PyF101 M-MuLV sc 2 0 0 0
11-1 wt M-MuLV sc 2 3.8 3 103 3.0 3 101 4.0 3 101
11-2 wt M-MuLV sc 2 1.5 3 103 1.2 3 101 5.0 3 100
10-3 Mo1PyF101 M-MuLV sc 4 0 0 0
10-4 Mo1PyF101 M-MuLV sc 4 0 0 0
11-3 wt M-MuLV sc 4 5.1 3 103 9.8 3 101 2.7 3 102
11-4 wt M-MuLV sc 4 4.6 3 103 4.9 3 101 3.6 3 101
12-1 Mo1PyF101 M-MuLV ip 2 0 0 0
12-2 Mo1PyF101 M-MuLV ip 2 0 0 0
13-1 wt M-MuLV ip 2 2.9 3 103 2.4 3 101 1.6 3 101
13-2 wt M-MuLV ip 2 5.9 3 103 9.0 3 101 3.2 3 101
12-3 Mo1PyF101 M-MuLV ip 4 0 1.5 3 100 ND
12-4 Mo1PyF101 M-MuLV ip 4 1.1 3 103 0.8 3 100 ND
13-3 wt M-MuLV ip 4 1.1 3 104 1.1 3 102 1.2 3 102
13-4 wt M-MuLV ip 4 5.8 3 103 1.4 3 102 ND
12-5 Mo1PyF101 M-MuLV ip 6 2.9 3 100 0 0
12-6 Mo1PyF101 M-MuLV ip 6 2.7 3 101 0 0
13-5 wt M-MuLV ip 6 2.8 3 103 2.3 3 102 1.5 3 102
13-6 wt M-MuLV ip 6 2.4 3 103 9.3 3 101 1.0 3 102
Note. ND, not done.
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fold). Thus, the pronounced in vivo defect of Mo1PyF101
M-MuLV infectivity in rats was not due to an intrinsic
inability of the virus to infect rat cells.
The second method of assessing in vitro infectivity
involved infections of REF52 and NIH-3T3 cells with
M-MuLV-based retroviral vectors. Since the only differ-
ence between Mo1PyF101 and wild-type M-MuLVs is
the inserted polyoma enhancers in the Mo1PyF101 LTR,
we tested whether the LTRs of these two viruses were
equally efficient in supporting viral infection in mouse
and rat cells in a single cycle of infection. The BAG
retroviral vector developed by Cepko expresses the bac-
terial b-galactosidase gene under control of an M-MuLV
LTR (Price et al., 1987). Helper-free stocks of BAG ob-
tained by transfection of the plasmid into Psi-2 packag-
ing cells (which express M-MuLV virion proteins (Mann
et al., 1983)) would infect the same cells as wild-type
M-MuLV, and each region of infection can be visualized
by staining with X-gal. Moreover, secondary effects re-
lated to the efficiency of viral spread are eliminated,
since only the initially infected cells are visualized. We
generated a modified version of BAG, in which the M-
MuLV LTR was replaced by the Mo1PyF101 LTR—
Mo1PyF101 BAG (Fig. 2). Stocks of Mo1PyF101 BAG
were also obtained by transfection of Psi-2 cells. The two
stocks were then infected onto NIH-3T3 and REF52 cells,
and the results are shown in Table 3. The Mo1PyF101
BAG vector showed equivalent infectivity relative to BAG
in both NIH-3T3 and REF52 cells. These results were
consistent with the endpoint dilution assays and con-
firmed that Mo1PyF101 M-MuLV is not defective relative
to wild-type M-MuLV for in vitro infection of rat cells
relative to mouse cells.
Tissue tropism of M-MuLV in rats
The infectious center assays of Table 1 indicated that
in rats wild-type M-MuLV infection is found predomi-
nantly in the thymus. Levels of infection in the thymus
were typically 100-fold higher than those in the spleen
and bone marrow, even at early times. In contrast, in
mice, M-MuLV infection in nonthymic hematopoietic tis-
sues is found at considerably higher levels (Belli and
Fan, 1994; Davis et al., 1986). A comparison of wild-type
M-MuLV infection in mice and rats is shown in Fig. 3.
While levels of infection in the thymus for the two species
were comparable by either route of infection, infection in
the bone marrow and the spleen was much less efficient
in rats than in mice. Indeed, in rats, M-MuLV infection
initially appeared to be largely confined to the thymus; at
later times infection in the spleen and the bone marrow
increased somewhat.
Decreased thymic cellularity in M-MuLV-infected rats
Another interesting phenomenon observed in M-MuLV-
infected rats was that the cellularity of infected thymuses
was depressed relative to uninfected animals at early
times. Table 4 shows counts of cells recovered from
thymus, spleen, and bone marrow (cellularity) of the
same animals shown in Table 1. In general, the thymuses
of wild-type M-MuLV-infected animals at 2 and 4 weeks
postinfection showed substantially fewer thymocytes
than thymuses from Mo1PyF101 M-MuLV-infected ani-
mals, in which little or no virus infection was evident.
(The Mo1PyF101 M-MuLV-infected rats were essentially
equivalent to uninfected animals, particularly at 2 weeks,
see Table 1.) The only potential exception was the
Mo1PyF101 M-MuLV-infected animal 12-4, which showed
noticeable thymic infection but the same level of thymic
cellularity as another animal of the same age (12-3).
However, the two age-matched wild-type M-MuLV-in-
fected rats showed 5- to 10-fold more virus infection than
animal 12-4. These results indicate that M-MuLV infec-
tion negatively affects the cellularity of thymuses in rats.
In general there were no consistent differences in
cellularity of the spleen or bone marrow of wild-type
TABLE 2
Infectivity of Wild-Type and Mo1PyF101 M-MuLV
on Rat and Mouse Cellsa
Virus Cell Dilution Infected culturesb
M-MuLV NIH-3T3 1023 3/3 (111)
1024 3/3 (111)
1025 3/3 (111)
1026 3/3 (111)
1027 0/3
1028 0/3
Mo1PyF101 M-MuLV NIH-3T3 1023 3/3 (111)
1024 3/3 (111)
1025 3/3 (111)
1026 3/3 (111)
1027 2/3 (111)
1028 0/3
M-MuLV REF52 1021 3/3 (111)
1022 3/3 (111)
1023 3/3 (11)
1024 2/3 (1)
1025 0/3
1026 0/3
Mo1PyF101 M-MuLV REF52 1021 3/3 (111)
1022 3/3 (111)
1023 3/3 (11)
1024 0/3
1025 0/3
1026 0/3
a Three independent cultures were infected with each dilution of
virus and passaged five times as described under Materials and
Methods. The cultures were then stained with a monoclonal antibody
for reaction with M-MuLV SU protein and scored for infection by
fluorescence microscopy.
b Number of positive cultures of the total are indicated. (111)
Confluently infected cultures; (11) cultures in which at least five
infected cells were observed in every microscope field; (1) at least five
infected cells in the well.
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M-MuLV-infected rats. The significance of a potential
decrease in bone marrow cellularity at 2 weeks in ip-
infected animals was unclear in light of the fact that this
tissue showed a substantially lower level of infection
than the thymus. Likewise, there was a potential in-
crease in splenic cellularity in ip-infected animals at 4
and 6 weeks, but the levels of splenocyte infection were
also lower than the levels of thymocyte infection.
DISCUSSION
In this report, the leukemogenesis of Mo1PyF101 M-
MuLV in rats was tested. Our initial hypothesis was that
Mo1PyF101 M-MuLV would show equivalent pathoge-
nicity to wild-type M-MuLV, since the leukemogenic de-
fect for Mo1PyF101 M-MuLV in mice is associated with
the lack of MCF recombinant formation, and rats do not
generate MCF recombinants because they lack the do-
nor endogenous polytropic proviruses. The slower time
course of disease by wild-type M-MuLV in rats might
have reflected the fact that they do not generate MCF
recombinants. Contrary to our expectations, Mo1PyF101
M-MuLV showed a complete lack of pathogenicity in
rats, after either sc or ip inoculation.
Further examination of Mo1PyF101 M-MuLV-infected
rats indicated that in vivo infection is extremely inefficient.
However, Mo1PyF101 and wild-type M-MuLV had approx-
imately equivalent infectivities on rat cells in culture, so
the in vivo block to infection does not reflect a universal
nonpermissiveness of rat cells for Mo1PyF101 M-MuLV.
Thus, Mo1PyF101 M-MuLV infection in rats differs from
infection in mice where similar levels of infection are
observed in most tissues. We have suggested that in
mice a cell type that is restricted for Mo1PyF101 M-
MuLV infection is one that delivers infection of wild-type
M-MuLV from the site of sc inoculation to the bone
marrow (Belli and Fan, 1994). In contrast, delivery of virus
to the bone marrow from an ip inoculation in mice either
uses a cell that is not restricted for Mo1PyF101 M-MuLV
FIG. 2. BAG vectors. The genetic organization of the BAG vector plasmid (Price et al., 1987) is shown. When transfected into retroviral packaging
cells, the region between the two LTRs will be transferred to recipient cells by reverse transcription and integration. The organization of a modified
BAG vector plasmid containing the Mo1PyF101 LTR (Mo1PyF101 BAG) is also shown. Upon transfection into retroviral packaging cells and infection
of recipient cells, the organization between the LTRs will be transferred. In addition, during the reverse transcription process, the Mo1PyF101 LTR
will appear in both upstream and downstream positions. We confirmed that Psi-2 cells transfected with the Mo1PyF101 BAG plasmid led to transfer
of retroviral vector provirus with the Mo1PyF101 LTRs on both sides (not shown).
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expression, or the virus gains access to the bone marrow
without infecting an intermediary cell. In the case of rats,
it is possible that the cells that deliver viral infection from
both sc or ip inoculations to the thymus (the major site of
replication) are restricted for Mo1PyF101 but not wild-
type M-MuLV infection.
An interesting result from these studies was the find-
ing that wild-type M-MuLV is much more thymotropic in
rats than in mice. At early times (2–4 weeks postinfec-
tion), the level of infection in thymocytes was typically 2
logs higher than that in other hematopoietic tissues. This
difference is not so great in mice. We and others have
suggested that in mice the infection of other hematopoi-
etic tissues such as the bone marrow and the spleen is
important for M-MuLV leukemogenesis (Asjo et al., 1985;
Storch et al., 1985; Davis et al., 1987; Fan, 1994). Thus, the
fact that there is little infection outside of the thymus in
rats (particularly at early times) suggests that M-MuLV
leukemogenesis in rats may involve infection only of the
thymus. M-MuLV leukemogenesis in rats and mice ap-
pears to be substantially different, with leukemogenesis
in mice involving infection of both nonthymic and thymic
tissues accompanied by generation of MCF recombi-
nants, while leukemogenesis in rats may only involve
infection of the thymus and be independent of MCFs.
One other phenomenon appeared to be associated with
early thymic infection in rats: decreased cellularity. We have
not observed equivalent early differences in the cellularity
of thymuses in infected vs uninfected mice. The mecha-
nisms involved in the decreased cellularity of infected rat
thymuses are unclear. The cell population in the young
thymus is very dynamic, with constant turnover of thymo-
cytes through immigration of thymocyte precursors, division
of thymocytes, emmigration of mature thymocytes, and
elimination by apoptosis. The size and cellularity of the
thymus will be dependent upon the balance of these pro-
cesses. It remains to be determined if reduction of thymic
FIG. 3. Tissue specificity of M-MuLV infection in mice and rats. (A)
Neonatal NIH Swiss and F344 rats were infected with wild-type M-
MuLV either sc or ip. At different times, bone marrow was recovered
from the animals and the level of infection was determined by infec-
tious center assays using XC cells as indicators. Each point represents
values from a different animal. (B) Levels of infection in splenocytes
from infected rats and mice are shown. (C) Levels of infection in
thymocytes are shown. Note that the levels of thymic infection are the
same for mice and rats, but that rats show substantially less infection
of bone marrow and splenocytes than do mice.
TABLE 3
Infection of NIH-3T3 and REF52 Cells with BAG
and Mo1PyF101 BAG Vectorsa
Vector Cell Dilution X-gal1 Colonies
BAG NIH-3T3 1022 TMTCb
1023 ,50
1024 12
1025 0
Mo1PyF101 BAG NIH-3T3 1022 TMTC
1023 ,50
1024 19
1025 3
BAG REF52 1022 TMTC
1023 26
1024 1
1025 0
Mo1PyF101 BAG REF52 1022 TMTC
1023 33
1024 2
1025 0
a NIH-3T3 or REF52 cell cultures were infected with serial dilutions of
helper-free BAG and Mo1PyF101 BAG vector stocks as described
under Materials and Methods. After the cultures reached confluency,
they were stained with X-gal, and the number of blue colonies per plate
was counted. The same vector stocks were used for infection of the
NIH-3T3 and REF-52 cells.
b Too many to count.
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cellularity in infected rats results from a direct effect of viral
infection on infected cells or from an indirect effect. An
example of a possible indirect effect would be if M-MuLV-
infected thymic stromal cells are altered in their production
of cytokines or apoptotic signaling molecules. The data in
Table 1 indicated that fewer than 10% of the thymocytes
from wild-type M-MuLV-infected rats scored as infectious
centers, which might support an indirect mechanism. How-
ever, in M-MuLV-infected mice we have observed that while
thymocyte infectious center assays may reach maximal
values ranging from 5 to 50%, 100% of the cells will stain
positively for M-MuLV antigen by flow cytometry (B. K.
Brightman and B. R. Davis, unpublished). Thus, the infec-
tious center assays may not score every infected cell. It
therefore remains possible that the decrease in thymic
cellularity could result directly from viral infection of the
thymocytes.
In summary, these experiments describe two differ-
ences between M-MuLV leukemogenesis in mice and
rats. First, the poor leukemogenicity of the Mo1PyF101
M-MuLV variant in rats involves a defect in establishing
infection, while in mice infection is established but other
preleukemic events (early infection of the bone marrow
and generation of MCF recombinants) are affected. Sec-
ond, wild-type M-MuLV infection in rats largely involves
the thymus (particularly at early times), while in mice
other hematopoietic organs are involved. It seems pos-
sible that leukemogenesis in rats may largely involve
insertional activation of proto-oncogenes, while in mice
other virus-driven events occur.
MATERIALS AND METHODS
Cells and viruses
Wild-type and Mo1PyF101 M-MuLV have been de-
scribed previously (Davis et al., 1985). Virus stocks con-
sisted of clarified and frozen supernatants from produc-
tively infected cells.
Infection of rats
Neonatal Fisher F334 rats were inoculated sc or ip with
wild-type or Mo1PyF101 M-MuLV (200 ml per animal). Wild-
type M-MuLV titers ranged from 2 to 8 3 103 XC PFU/ml,
and Mo1PyF101 M-MuLV titers ranged from 1 3 104 to
1.5 3 105 XC PFU/ml. Animals were monitored regularly,
and moribund animals were sacrificed by CO2 inhalation.
Tumor tissues were stored at 280°C for extraction of nu-
cleic acids and tumor diagnosis. For time course studies,
infected animals were sacrificed and cell suspensions from
thymus, spleen, and bone marrow were prepared as de-
scribed previously (Davis et al., 1986). NIH Swiss mice were
inoculated in parallel with the rats and used in infectious
center time course studies.
Virus assays
M-MuLV infectivities were determined on NIH-3T3
cells by the XC syncitial assay (Rowe et al., 1970). For
infectivity on rat cells, triplicate cultures of REF52 cells
(provided by Dr. Philip Tsichlis) and NIH-3T3 cells
were infected with serial dilutions ranging from 1021 to
1028 of wild-type and Mo1PyF101 M-MuLV stocks (1
TABLE 4
Cellularity of Hematopoietic Tissues in M-MuLV-Infected Rats
Rat No. Inoculum Inoculation route Age (weeks)
Cell number
Thymus Spleen Bone marrow
10-1 Mo1PyF101 M-MuLV sc 2 2.0 3 108 1.5 3 108 3.2 3 107
10-2 Mo1PyF101 M-MuLV sc 2 2.0 3 108 1.1 3 108 4.0 3 107
11-1 wt M-MuLV sc 2 1.1 3 108 0.8 3 108 4.5 3 107
11-2 wt M-MuLV sc 2 1.1 3 108 0.8 3 108 3.0 3 107
10-3 Mo1PyF101 M-MuLV sc 4 3.2 3 108 2.5 3 108 7.2 3 107
10-4 Mo1PyF101 M-MuLV sc 4 3.1 3 108 2.0 3 108 6.6 3 107
11-3 wt M-MuLV sc 4 2.0 3 108 3.2 3 108 5.9 3 107
11-4 wt M-MuLV sc 4 2.1 3 108 3.2 3 108 10.0 3 107
12-1 Mo1PyF101 M-MuLV ip 2 1.6 3 108 1.0 3 108 4.2 3 107
12-2 M01PyF101 M-MuLV ip 2 1.9 3 108 1.4 3 108 3.1 3 107
13-1 wt M-MuLV ip 2 0.6 3 108 0.9 3 108 2.0 3 107
13-2 wt M-MuLV ip 2 0.3 3 108 0.9 3 108 1.8 3 107
12-3 Mo1PyF101 M-MuLV ip 4 2.1 3 108 2.1 3 108 ND
12-4 Mo1PyF101 M-MuLV ip 4 2.1 3 108 2.7 3 108 ND
13-3 wt M-MuLV ip 4 1.2 3 108 4.3 3 108 ND
13-4 wt M-MuLV ip 4 1.1 3 108 4.1 3 108 ND
12-5 Mo1PyF101 M-MuLV ip 6 3.2 3 108 4.6 3 108 16.0 3 107
12-6 Mo1PyF101 M-MuLV ip 6 4.0 3 108 3.6 3 108 18.0 3 107
13-5 wt M-MuLV ip 6 3.1 3 108 6.6 3 108 17.0 3 107
13-6 wt M-MuLV ip 6 4.0 3 108 11.2 3 108 8.4 3 107
Note. ND, not done.
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ml of dilution per 5-cm dish containing 5 3 104 cells).
Each infected culture was then transferred upon
reaching confluency for a total of five times. During the
fifth transfer, 1.5 3 104 cells from each culture were
seeded into wells of 96-well microtiter tissue culture
dishes. Upon reaching confluency, the wells were
stained with a rat monoclonal antibody specific for
M-MuLV gp70 protein (MAb 548 (Chesebro et al.,
1983)), followed by secondary staining with a FITC-
conjugated goat anti-rat MAb. The microtiter wells
were examined by fluorescence microscopy.
BAG and Mo1PyF101 BAG assays
The BAG vector plasmid was obtained from Dr. Con-
stance Cepko (Price et al., 1987). This is an M-MuLV-
based vector that expresses bacterial b-galactosidase
as a fusion protein with M-MuLV gag, and it also con-
tains a cassette for expression of the bacterial neomycin
resistance gene. Helper-free vector stock was prepared
by transfecting the BAG vector plasmid into Psi-2 cells [a
retroviral packaging line expressing M-MuLV proteins
(Mann et al., 1983)] followed by selection of vector-ex-
pressing cells by growth in G418. Individual G418-resis-
tant colonies were screened for level of BAG production,
and supernatant from a producer clone was clarified and
frozen for experiments.
A modified BAG vector plasmid containing the
Mo1PyF101 LTR at the 39 end was molecularly cloned.
Details of the molecular cloning will be provided upon
request. Mo1PyF101 BAG vector stocks were also ob-
tained by transfection of Psi-2 cells, selection of G418-
resistant colonies, and harvest and storage of culture
supernatants as described above.
Infections of NIH-3T3 and REF52 cells with the BAG
and Mo1PyF101 BAG vector stocks were carried out in
monolayers as described previously (Fan et al., 1986;
Price et al., 1987). When the infected monolayers
reached confluency, they were stained with X-gal, and
the number of blue colonies was counted.
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